MX2015011588A - Tratamiento de combinacion. - Google Patents

Tratamiento de combinacion.

Info

Publication number
MX2015011588A
MX2015011588A MX2015011588A MX2015011588A MX2015011588A MX 2015011588 A MX2015011588 A MX 2015011588A MX 2015011588 A MX2015011588 A MX 2015011588A MX 2015011588 A MX2015011588 A MX 2015011588A MX 2015011588 A MX2015011588 A MX 2015011588A
Authority
MX
Mexico
Prior art keywords
taxane
pharmaceutically acceptable
acceptable salt
compound
treatment
Prior art date
Application number
MX2015011588A
Other languages
English (en)
Other versions
MX362905B (es
Inventor
Barry Robert Davies
Ursula Joy Hancox
Sabina Cosulich
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2015011588A publication Critical patent/MX2015011588A/es
Publication of MX362905B publication Critical patent/MX362905B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere al uso de combinaciones que comprenden 8-[(1R)-1-(3,5-difluorofenilamino)etil]-N,N-dimetil-2-m orfolino-4-oxo-4H-cromeno-6-carboxamida o una sal farmacéuticamente aceptable de la misma y un taxano en el tratamiento o profilaxis de cáncer; composiciones farmacéuticas que comprenden el Compuesto [I] (o una sal farmacéuticamente aceptable del mismo) y un taxano; kits que comprenden el Compuesto [I] o una sal farmacéuticamente aceptable del mismo y un taxano, opcionalmente con instrucciones para su uso; y métodos de tratamiento que comprenden la administración simultánea, secuencial o separada del Compuesto [I] o una sal farmacéuticamente aceptable del mismo y un taxano a un animal de sangre caliente, tal como el hombre.
MX2015011588A 2013-03-04 2014-03-03 Tratamiento de combinacion. MX362905B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771974P 2013-03-04 2013-03-04
US201361772079P 2013-03-04 2013-03-04
PCT/GB2014/050618 WO2014135851A1 (en) 2013-03-04 2014-03-03 Combination treatment

Publications (2)

Publication Number Publication Date
MX2015011588A true MX2015011588A (es) 2015-12-09
MX362905B MX362905B (es) 2019-02-25

Family

ID=50288179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011588A MX362905B (es) 2013-03-04 2014-03-03 Tratamiento de combinacion.

Country Status (13)

Country Link
US (1) US9763950B2 (es)
EP (1) EP2964217B1 (es)
JP (1) JP6546098B2 (es)
KR (1) KR102222346B1 (es)
CN (1) CN105142629B (es)
AU (1) AU2014224445C1 (es)
BR (1) BR112015019524A8 (es)
CA (1) CA2900136C (es)
ES (1) ES2754034T3 (es)
HK (1) HK1216391A1 (es)
MX (1) MX362905B (es)
RU (1) RU2666999C2 (es)
WO (1) WO2014135851A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019178024A1 (en) * 2018-03-16 2019-09-19 Dfb Soria, Llc Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634994B2 (en) 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2294981C (en) 1997-06-27 2012-04-03 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
RU2284818C2 (ru) * 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
NZ538420A (en) 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
RU2006124421A (ru) 2003-12-09 2008-01-20 ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения
KR101457834B1 (ko) 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
CN104189905A (zh) 2005-08-31 2014-12-10 阿布拉科斯生物科学有限公司 包含水难溶性药剂和抗微生物剂的组合物
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
WO2012131399A1 (en) * 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
MX362905B (es) 2019-02-25
CA2900136C (en) 2021-05-04
AU2014224445B2 (en) 2017-02-02
BR112015019524A2 (pt) 2017-07-18
JP2016510060A (ja) 2016-04-04
ES2754034T3 (es) 2020-04-15
BR112015019524A8 (pt) 2019-11-19
KR20150122145A (ko) 2015-10-30
HK1216391A1 (zh) 2016-11-11
AU2014224445A1 (en) 2015-08-27
EP2964217B1 (en) 2019-08-28
EP2964217A1 (en) 2016-01-13
CA2900136A1 (en) 2014-09-12
RU2666999C2 (ru) 2018-09-13
AU2014224445C1 (en) 2017-07-27
US20160022690A1 (en) 2016-01-28
CN105142629B (zh) 2018-11-23
RU2015139515A (ru) 2017-04-10
WO2014135851A1 (en) 2014-09-12
US9763950B2 (en) 2017-09-19
JP6546098B2 (ja) 2019-07-17
CN105142629A (zh) 2015-12-09
KR102222346B1 (ko) 2021-03-02

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12016502355B1 (en) Pharmaceutical composition
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
GB201118656D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
IN2014MN02236A (es)
MX2016001683A (es) Combinaciones de inhibidores de quinasa pim.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX362905B (es) Tratamiento de combinacion.
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
IN2014DN03010A (es)
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.

Legal Events

Date Code Title Description
FG Grant or registration